Iterum Therapeutics plc (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem [Yahoo! Finance]
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
Iterum Therapeutics plc (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]